| Tumor Targeting in Cancer Therapy 2002 Edition Contributor(s): Pagé, Michel (Editor) |
|
 |
ISBN: 0896039196 ISBN-13: 9780896039193 Publisher: Humana OUR PRICE: $208.99 Product Type: Hardcover - Other Formats Published: April 2002 Annotation: In Tumor Targeting in Cancer Therapy, Dr. Michel Pag?? and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their applications from laboratory to bedside. By concisely synthesizing the many technical details, the authors illuminate this innovative technique, ranging from the fundamentals of drug targeting and in vivo and in vitro experimentation, to such emerging therapeutic uses as radioimmunotherapy, radioimmunodetection, therapy with cytotoxic antibodies, immunotoxins, enzyme prodrug immunotherapy, and immunotherapeutics with fusion proteins. There are also reviews of targeting tumors with radioimmunoconjugates, photodynamic therapy, and magnetic drugs, as well as discussions of the internalization of antibodies, bioconjugation and biodistribution, the use of cytotoxic drugs, and the pros and cons of targeting by antibody or ligand. |
| Additional Information |
| BISAC Categories: - Medical | Oncology - General - Medical | Pharmacology - Medical | Pharmacy |
| Dewey: 616.994 |
| LCCN: 2001051657 |
| Series: Cancer Drug Discovery & Development |
| Physical Information: 1.24" H x 7.2" W x 10.38" (2.53 lbs) 463 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: In Tumor Targeting in Cancer Therapy, Dr. Michel Pag and a panel of authoritative experts from the drug industry, clinics, and academia introduce the principles and techniques of tumor targeting and critically survey their applications from laboratory to bedside. By concisely synthesizing the many technical details, the authors illuminate this innovative technique, ranging from the fundamentals of drug targeting and in vivo and in vitro experimentation, to such emerging therapeutic uses as radioimmunotherapy, radioimmunodetection, therapy with cytotoxic antibodies, immunotoxins, enzyme prodrug immunotherapy, and immunotherapeutics with fusion proteins. There are also reviews of targeting tumors with radioimmunoconjugates, photodynamic therapy, and magnetic drugs, as well as discussions of the internalization of antibodies, bioconjugation and biodistribution, the use of cytotoxic drugs, and the pros and cons of targeting by antibody or ligand. |